Pharmacological effects of Yindan Pinggan capsules in treating intrahepatic cholestasis
10.16438/j.0513-4870.2024-1117
- VernacularTitle:茵胆平肝胶囊治疗肝内胆汁淤积症的药效作用研究
- Author:
Shu-xin CAO
1
;
Feng HUANG
2
;
Fang WU
3
;
Rong-rong HE
4
Author Information
1. School of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming 650500, China; Guangdong Provincial Engineering Technology Research Center for Disease Susceptibility and Development of Traditional Chinese Medicine/Guangdong-Hong Kong-Macao Joint Laboratory for Internationalization of Traditional Chinese Medicine Research, Jinan University, Guangzhou 510632, China; Guangdong Provincial Key Laboratory for Research on the Pharmacological Basis of Traditional Chinese Medicine and Innovative Drugs, School of Pharmacy, Jinan University, Guangzhou 510632, China; Ministry of Education International Cooperation Joint Laboratory of Traditional Chinese Medicine and Innovative Drugs, Jinan University, Guangzhou 510632, China
2. School of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming 650500, China
3. Guangdong Provincial Engineering Technology Research Center for Disease Susceptibility and Development of Traditional Chinese Medicine/Guangdong-Hong Kong-Macao Joint Laboratory for Internationalization of Traditional Chinese Medicine Research, Jinan University, Guangzhou 510632, China; Guangdong Provincial Key Laboratory for Research on the Pharmacological Basis of Traditional Chinese Medicine and Innovative Drugs, School of Pharmacy, Jinan University, Guangzhou 510632, China; Ministry of Education International Cooperation Joint Laboratory of Traditional Chinese Medicine and Innovative Drugs, Jinan University, Guangzhou 510632, China; Department of Critical Care Medicine, Guangdong Provincial Second People's Hospital, Guangzhou 510317, China
4. School of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming 650500, China; Guangdong Provincial Engineering Technology Research Center for Disease Susceptibility and Development of Traditional Chinese Medicine/Guangdong-Hong Kong-Macao Joint Laboratory for Internationalization of Traditional Chinese Medicine Research, Jinan University, Guangzhou 510632, China; Guangdong Provincial Key Laboratory for Research on the Pharmacological Basis of Traditional Chinese Medicine and Innovative Drugs, School of Pharmacy, Jinan University, Guangzhou 510632, China; Ministry of Education International Cooperation Joint Laboratory of Traditional Chinese Medicine and Innovative Drugs, Jinan University, Guangzhou 510632, China; Department of Critical Care Medicine, Guangdong Provincial Second People's Hospital, Guangzhou 510317, China
- Publication Type:Research Article
- Keywords:
Yindan Pinggan capsules;
intrahepatic cholestasis;
network pharmacology;
PI3K-AKT signaling pathway;
clearing heat and promoting dampness;
inflammatory response
- From:
Acta Pharmaceutica Sinica
2025;60(2):417-426
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to investigate the therapeutic effect of Yindan Pinggan capsules (YDPG) on intrahepatic cholestasis (IHC) through animal experiments, while utilizing network pharmacology and molecular docking techniques to explore its potential mechanisms. Initially, the therapeutic effect of YDPG on an α-naphthylisothiocyanate (ANIT)-induced IHC mouse model was assessed through liver function tests, routine blood tests, and liver pathology analysis. Subsequently, network pharmacology tools were employed to predict the active components, core targets, and signaling pathways of YDPG. Molecular docking technology was employed to verify the binding activity of key active components of YDPG with core targets, followed by protein immunoblotting to validate the key targets. Results showed that YDPG significantly improved liver function abnormalities and hepatocyte damage in IHC mice. Network pharmacology analysis revealed that 94 active components in YDPG were associated with 396 targets for the treatment of IHC, and were significantly enriched in pathways such as the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) signaling pathway, lipid metabolism, and bile secretion. Molecular docking results showed good binding activity between key active components of YDPG and core targets of the PI3K-AKT signaling pathway. Further protein immunoblotting confirmed that YDPG could reduce the phosphorylation levels of PI3K and AKT proteins, core targets of the PI3K-AKT pathway in liver tissue. These findings suggest that YDPG may alleviate biological processes such as oxidative stress and inflammatory responses by regulating the PI3K-AKT signaling pathway, thereby improving liver damage in IHC mice and exerting a therapeutic effect on IHC. This experiment has been approved by the Animal Experiment Ethics Committee of Jinan University (ethical approval number: IACUC-20241011-09).
